Zyneyro

Executive Summary

Zyneyro is a Danish biotechnology company founded in 2020, leveraging over 20 years of research from the University of Copenhagen to develop innovative therapies for chronic pain. Its lead program, ZYNPN, is a novel synthetic peptide therapy targeting maladaptive neural plasticity associated with neuropathic pain. Unlike current treatments such as opioids or gabapentinoids, ZYNPN is designed to avoid side effects and addiction risks. The company operates in the neuroscience and digital health categories, reflecting a data-driven approach to pain management. As a private, early-stage company with no disclosed funding or clinical milestones, Zyneyro represents a high-risk, high-reward opportunity in the chronic pain space. Its differentiation lies in targeting the underlying neural plasticity mechanisms rather than symptom modulation, potentially offering disease-modifying benefits. However, the absence of publicly available clinical data or regulatory filings limits near-term visibility. The key challenge will be securing financing and advancing ZYNPN through preclinical and early clinical development.

Upcoming Catalysts (preview)

• H2 2026Release of preclinical efficacy data for ZYNPN in neuropathic pain models70% success
• H2 2026Series A financing round to support IND-enabling studies50% success
• Q1 2027Announcement of partnership with a CRO for regulatory and manufacturing support60% success